Experience

• • Oaktree Capital Management as a lead investor in the $890 million recapitalization of Patriot National Bancorp, parent company of a nationally chartered bank, in its merger with American Challenger, an entity formed in 2020 to establish a new digital national bank.
  • Deutsche Bank Securities, as financial advisor to Trinseo, in the $491 million sale of Trinseo’s synthetic rubber business to Synthos.
  • Kindred Healthcare in the sale of its RehabCare business line, a provider of contract therapy services in 43 states, to Select Rehabilitation, a leading provider of contract rehabilitation services.
  • Funds managed by Oaktree Capital Management in their investment in a Quid Capital venture, which will offer liquidity benefits to shareholders of high-growth private technology companies.
  • Funds managed by Oaktree Capital Management in the launch of Encina Lender Finance, a new independent lender finance platform targeting commercial and consumer specialty finance companies in the United States and Canada.
  • Allergan in its sale of Brazikumab to AstraZeneca and Zenpep to Nestle.
  • Amazon as strategic partner to Yankee Global Enterprises in the acquisition of the YES Network from The Walt Disney Company at a total enterprise value of $3.47 billion.
  • J.P. Morgan Securities, as financial advisor to Quad/Graphics, in Quad/Graphics's $1.4 billion acquisition of LSC Communications. (Terminated)
  • TPG and Welsh, Carson, Anderson & Stowe in the $4.1 billion acquisition of Kindred Healthcare.
  • Temasek in its strategic investment in BluJay Solutions, a leading provider of supply chain software and services.
  • RWL Water in the merger by acquisition of Emefcy Group and RWL Water.
  • Littlejohn & Co. in the sale of a minority interest in the firm’s management companies and general partners to Goldman Sachs Alternative Investments & Manager Selection (AIMS) Group.
  • Guardian in its sale of RS Investments to Victory Capital.
  • J.P. Morgan Securities, as financial advisor to Allergan, in Allergan's $40.5 billion sale of a generics unit to Teva Pharmaceutical Industries.